1-(39-((2,5-dioxopyrrolidin-1-yl)oxy)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontyl)triaza-1,2-dien-2-ium

Catalog No. :
ACSAFX043
CAS No. :
1610796-02-5
Molecular Formula :
C31H57N4O16+
Molecular Weight :
741.81

IUPAC Name:1-(39-((2,5-dioxopyrrolidin-1-yl)oxy)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontyl)triaza-1,2-dien-2-ium

1-(39-((2,5-dioxopyrrolidin-1-yl)oxy)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontyl)triaza-1,2-dien-2-ium structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(39-((2,5-dioxopyrrolidin-1-yl)oxy)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontyl)triaza-1,2-dien-2-ium
IUPAC Name1-(39-((2,5-dioxopyrrolidin-1-yl)oxy)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontyl)triaza-1,2-dien-2-ium
MDL No.-
Molecular FormulaC31H57N4O16+
Molecular Weight741.81
SMILESN=[N+]=NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O
InChI KeyHXWIYWXCECDXCB-UHFFFAOYSA-N
SynonymAzido-PEG12-NHS ester;N3-PEG12-CH2CH2COONHS Ester;NHS-PEG12-azide;2,5-dioxopyrrolidin-1-yl 40-azido-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxatetracontanoate
CAS No.1610796-02-5

Synthetic Route by SureRoute

1. ACSAFX043 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSAFX043 route product structure diagram
    ACSAFX0431610796-02-5
Inquiry

2. ACSAFX043 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSAFX043 route product structure diagram
    ACSAFX0431610796-02-5
Inquiry

Comments (0)